Rebecca T. Horwitz
Bartlit Beck LLP, 2013-Present, Partner (since 2019)
Cases tried or otherwise taken to judgment
Merck & Cie v. Watson Labs (D. Del., 2015)
Trial counsel for Merck & Cie and its exclusive licensee Bayer in Hatch-Waxman litigation against challenger seeking to market generic versions of the oral contraceptives Beyaz® and Safyral®. Complete trial victory for Merck and Bayer; case pending on appeal.
Drake v. Allergan (D. Vermont, 2014)
Trial Counsel for Allergan in case involving claim that BOTOX® caused pediatric patient treated for muscle spasticity to experience seizures. Cross-examined life-care expert. Following a two-week trial, jury returned verdict for plaintiffs.
Other representative cases
Gilead Sciences v. Mylan Pharmaceuticals (D. Del.)
Counsel for Gilead in Hatch-Waxman litigation relating to Gilead’s Tybost® (cobicistat) product. Case pending.
U.S. Airways v. Sabre Inc. (S.D.N.Y. 2011-present)
Trial counsel for Sabre in U.S. Airways' antitrust action concerning Sabre’s Global Distribution System. Trial set for October 2016.
Botox Litigation (Nationwide, 2013-2015)
Counsel for Allergan in cases involving allegations that BOTOX® causes various injuries. Obtained favorable settlements in three of the four cases in which we represent Allergan. Tried the fourth case to a jury verdict for plaintiffs.
- Merck & Cie, et. al. v. Watson Labs (Beyaz®/Safyral® Litigation) (D. Del. 2015)